Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AFMD NASDAQ:BFRG NASDAQ:MRKR NASDAQ:PHIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.18-34.9%$0.25$0.07▼$5.48$2.92M2.074.87 million shs22.99 million shsBFRGBullfrog AI$1.33+2.1%$1.35$1.09▼$4.84$13.11M0.4690,307 shs73,904 shsMRKRMarker Therapeutics$0.95-1.6%$1.28$0.81▼$5.95$12.55M1.522.69 million shs152,925 shsPHIOPhio Pharmaceuticals$2.18-6.0%$2.28$0.97▼$9.79$13.29M0.89141,356 shs115,295 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed0.00%0.00%0.00%0.00%-95.29%BFRGBullfrog AI+2.08%+16.40%-0.23%-21.48%-45.61%MRKRMarker Therapeutics-1.60%+6.45%-26.00%-40.34%-65.66%PHIOPhio Pharmaceuticals-6.03%+6.86%-0.46%-3.96%-21.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.18-34.9%$0.25$0.07▼$5.48$2.92M2.074.87 million shs22.99 million shsBFRGBullfrog AI$1.33+2.1%$1.35$1.09▼$4.84$13.11M0.4690,307 shs73,904 shsMRKRMarker Therapeutics$0.95-1.6%$1.28$0.81▼$5.95$12.55M1.522.69 million shs152,925 shsPHIOPhio Pharmaceuticals$2.18-6.0%$2.28$0.97▼$9.79$13.29M0.89141,356 shs115,295 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed0.00%0.00%0.00%0.00%-95.29%BFRGBullfrog AI+2.08%+16.40%-0.23%-21.48%-45.61%MRKRMarker Therapeutics-1.60%+6.45%-26.00%-40.34%-65.66%PHIOPhio Pharmaceuticals-6.03%+6.86%-0.46%-3.96%-21.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFMDAffimed 2.00Hold$3.621,895.87% UpsideBFRGBullfrog AI 0.00N/AN/AN/AMRKRMarker Therapeutics 3.50Strong Buy$13.171,279.29% UpsidePHIOPhio Pharmaceuticals 3.00Buy$14.00542.20% UpsideCurrent Analyst Ratings BreakdownLatest AFMD, PHIO, MRKR, and BFRG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.006/25/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFMDAffimed$877K3.33N/AN/A$4.19 per share0.04BFRGBullfrog AI$33.26K402.25N/AN/A$0.57 per share2.33MRKRMarker Therapeutics$6.59M1.87N/AN/A$1.73 per share0.55PHIOPhio PharmaceuticalsN/AN/AN/AN/A$0.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFMDAffimed-$114.66MN/A0.00N/AN/A-7,836.26%-193.84%-107.24%N/ABFRGBullfrog AI-$6.99M-$0.76N/A∞N/AN/A-195.35%-162.37%N/AMRKRMarker Therapeutics-$10.73M-$1.37N/AN/AN/A-271.12%-114.59%-90.31%11/13/2025 (Estimated)PHIOPhio Pharmaceuticals-$7.15M-$3.25N/A0.58N/AN/A-88.75%-77.98%11/13/2025 (Estimated)Latest AFMD, PHIO, MRKR, and BFRG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MRKRMarker Therapeutics-$0.55-$0.29+$0.26-$0.29$0.72 million$0.86 million8/14/2025Q2 2025PHIOPhio Pharmaceuticals-$0.36-$0.45-$0.09-$0.45N/AN/A8/13/2025Q2 2025BFRGBullfrog AIN/A-$0.15N/A-$0.15N/A$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAFMDAffimedN/AN/AN/AN/AN/ABFRGBullfrog AIN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFMDAffimed0.131.931.93BFRGBullfrog AIN/A3.973.97MRKRMarker TherapeuticsN/A3.453.45PHIOPhio PharmaceuticalsN/A9.369.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFMDAffimed30.82%BFRGBullfrog AI0.96%MRKRMarker Therapeutics22.39%PHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipAFMDAffimed3.80%BFRGBullfrog AI24.72%MRKRMarker Therapeutics7.80%PHIOPhio Pharmaceuticals0.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAFMDAffimed20016.10 million15.49 millionOptionableBFRGBullfrog AI410.08 million7.59 millionNot OptionableMRKRMarker Therapeutics6012.94 million11.93 millionNot OptionablePHIOPhio Pharmaceuticals105.73 million5.68 millionNot OptionableAFMD, PHIO, MRKR, and BFRG HeadlinesRecent News About These CompaniesPhio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | newsfilecorp.comNMerkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsightAugust 20, 2025 | finance.yahoo.comPhio Pharmaceuticals files to sell 1.93M shares of common stock for holdersAugust 15, 2025 | msn.comPhio Pharmaceuticals files to sell 1.93M shares for holdersAugust 15, 2025 | msn.comPhio Posts Wider Loss in Fiscal Q2August 14, 2025 | aol.comAPhio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | newsfilecorp.comNPhio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | newsfilecorp.comNPhio Pharmaceuticals stock soars after manufacturing agreementJuly 25, 2025 | za.investing.comPhio Pharmaceuticals Shares Rise After New Development Services AgreementJuly 25, 2025 | marketwatch.comPhio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross ProceedsJuly 25, 2025 | newsfilecorp.comNPhio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth CohortJuly 25, 2025 | newsfilecorp.comNPhio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug SubstanceJuly 25, 2025 | newsfilecorp.comNPhio Pharmaceuticals Corp. (PHIO) Latest Press Releases & Corporate ...July 16, 2025 | finance.yahoo.comPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer ... - FinanzNachrichten.deJune 27, 2025 | finanznachrichten.dePhio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation CohortJune 25, 2025 | newsfilecorp.comNPhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesJune 24, 2025 | newsfilecorp.comNPhio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA PortfolioJune 6, 2025 | newsfilecorp.comNBest Value Stocks to Buy for May 28thMay 28, 2025 | zacks.comNew Strong Buy Stocks for May 28thMay 28, 2025 | zacks.comPhio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor ConferenceMay 19, 2025 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAFMD, PHIO, MRKR, and BFRG Company DescriptionsAffimed NASDAQ:AFMDAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.Bullfrog AI NASDAQ:BFRG$1.33 +0.03 (+2.08%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$1.30 -0.03 (-2.03%) As of 09/12/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Marker Therapeutics NASDAQ:MRKR$0.95 -0.02 (-1.60%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.94 -0.01 (-1.01%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.Phio Pharmaceuticals NASDAQ:PHIO$2.18 -0.14 (-6.03%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.22 +0.03 (+1.61%) As of 09/12/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
